Alzheon is turning to the public markets to finance a new round of testing for its experimental Alzheimer’s disease drug.
The Framingham, MA, company set a preliminary $80 million target for its initial public stock offering. That figure is expected to change as Alzheon determines how many shares to sell and at what price. But the company may need more than $80 million. FDA approval could require two Phase 3 studies. Two years ago, Alzheon pegged that cost at more than $100 million.
Alzheon’s drug, ALZ-801, is a reworked version of tramiprosate, a drug that was meant to block the… Read more »
UNDERWRITERS AND PARTNERS